Pediatric Cancers, Next Generation Sequencing, Illumina technologies, Organoids

About the lab:

The establishment of cancer-derived organoids has recently begun to emerge as a prominent and promising tool to enhance our understanding of human cancers (Broutier et al., nature protocols 2016 & Broutier et al., nature medicine 2017). However, such models have as yet not been developed for pediatric cancers. The research program that we develop in the C3 lab forms part of this perspective with the objective to elaborate innovative organoid models to address pediatric cancers specificities and complexity, with a special focus on the mechanisms of resistance to treatments. We are affiliated to the Cancer Research Centre of Lyon (CRCL –INSERM U1052 / CNRS 5286) and to the Centre Léon Bérard’s Pediatric hospital (IHOPE). Our group is therefore composed of researchers (biologists & bioinformaticians), clinicians and pathologists.

The candidate will work with other bioinformaticians and biology researchers. In brief, the candidate will be responsible for processing and analyzing multi-scale omics data already available in the lab (targeted-DNAseq, RNA-seq (bulk and single cell (10X)), MethylEPIC 850K, and proteomic). The main focus of the candidate will be to explore, by using these datasets, mechanisms of resistance to treatment in pediatric gliomas and rhabdomyosarcomas. The key players identified by the candidate will be validated in the lab on organoid models. 

The successful applicant will initially have a 1-year contract, with the possibility of extension.

Salary:

Salary will follow the rules of the Cancer Research Center of Lyon (CRCL) and will depend on the experience of the candidates.

Candidate profile: